Novartis achieves trial success with ribociclib for breast cancer

19 May 2016
2019_biotech_test_vial_discovery_big

Swiss pharma giant Novartis (NOVN: VX) has been advised to stop its Phase III trial of LEE011 (ribociclib) for advanced breast cancer as it met the primary endpoint.

The Monaleesa-2 independent data monitoring committee has recommended stopping the trial early as it met the primary endpoint, significantly extending progression-free survival (PFS) compared to letrozole alone, at pre-planned interim analysis.

Monaleesa-2 is a pivotal Phase III trial of LEE011, a cyclin dependent kinase inhibitor (CDK4/6), in combination with letrozole, compared to letrozole alone.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology